Categories
Life Sciences Consumer Goods Materials and Chemicals Construction & Manufacturing Food and Beverages Energy and Power Semiconductor and Electronics Automotive and Transportation ICT & Media Aerospace & Defense BFSI

Int'l : +1-503-894-6022 | Toll Free : +1-800-792-5285 | help@alliedmarketresearch.com

Non-opioid Pain Patch Market by Patch Type (Capsaicin Patches, Lidocaine Patches, Diclofenac Patches, Ketoprofen Patches, Methyl Salicylate Patches, Others) and by Distribution Channel (Hospital Pharmacies, Online Pharmacies, Independent Pharmacies Drug Stores): Global Opportunity Analysis and Industry Forecast, 2023-2032

A03274

Pages: NA

Charts: NA

Tables: NA

There are a large number of people using opioid medication as painkillers. As per the statistics by the United Nations Office on Drugs and Crime, almost 26.4 to 36 million people abused opioid globally in 2012. Due to an increase in the rate of addiction and severe side-effects associated with the prolonged use of opioid medication there has been an increased demand for the use of non-opioid therapeutics. The mode of action of non-opioid medications are analgesic, antipyretic, and anti-inflammatory. These medications decrease the development of pain mediators in the peripheral nervous system by preventing the enzyme cyclooxygenase at the site of injury, which in turn blocks the production of prostaglandins.

The rise in the incidence of pain disorders has increased the demand for different approaches for pain management. In addition, an increase in costs-associated with the treatment and growing number of people with chronic and acute pain are some of the major driving factors for the market growth. Moreover, the growing awareness regarding the side-effects related with frequent opioid use has further boosted the demand for non-opioid medication. A rise in the abuse of opioid medication has also increased the R&D to develop non-opioid medication, which will further fuel the market growth. However, side-effects with prolonged and excessive use of non-opioid medication such as damage to the liver or kidneys can hamper the market growth.

The global non-opioid pain patch market is segmented based on patch type, distribution, and geography. Based on patch type, the market is segmented into capsaicin patches, lidocaine patches, diclofenac patches, ketoprofen patches, methyl salicylate patches, and others. Based on distribution channels, the market is categorized into hospital pharmacies, online pharmacies, independent pharmacies, and drug stores. Based on geography, the market has been examined across North America, Europe, Asia-Pacific, and LAMEA.

Comprehensive competitive analysis and profiles of major market players such as Teikoku Seiyaku Co., Ltd., Mylan N.V., GlaxoSmithKline plc, Teh Seng Pharmaceutical Mfg. Co., Ltd., Allergan, Pfizer, Inc., Hisamitsu Pharmaceutical Co. Inc., Acorda Therapeutics, and IBSA Institut Biochimque SA, Inc. have also been provided in this report.

Key Benefits

  • This report provides an extensive analysis of the current and emerging market trends and dynamics in the global market.
  • This report entails a detailed quantitative analysis of the current market and estimations which assists in identifying prevailing market opportunities.
  • The projections in this report are made by analyzing the current trends and future market potential in terms of value.
  • Competitive intelligence (of leading manufacturers and distributors of non-opioid pain patches) helps understand the competitive scenario globally.
  • An in-depth analysis of current research and clinical developments within the market has been provided with key market dynamic factors that help understand the behavior of the market.

 Key Market Segments

  • By Patch Type
    • Capsaicin Patches
    • Lidocaine Patches
    • Diclofenac Patches
    • Ketoprofen Patches
    • Methyl Salicylate Patches
    • Others
  • By Distribution Channel
    • Hospital Pharmacies
    • Online Pharmacies
    • Independent Pharmacies & Drug Stores
  • By Region
    • North America
      • U.S.
      • Canada
      • Mexico
    • Europe
      • France
      • Germany
      • Italy
      • Spain
      • UK
      • Rest of Europe
    • Asia-Pacific
      • China
      • Japan
      • India
      • South Korea
      • Australia
      • Rest of Asia-Pacific
    • LAMEA
      • Brazil
      • South Africa
      • Saudi Arabia
      • Rest of LAMEA

 
Key Market Players

  • Mylan N.V.
  • Endo Pharmaceuticals, Inc.
  • GlaxoSmithKline plc
  • Allergan plc
  • Hisamitsu Pharmaceutical Co. Inc.
  • Teh Seng Pharmaceutical Mfg. Co., Ltd.
  • IBSA Institut Biochimque SA, Inc.
  • Acorda Therapeutics
  • Teikoku Seiyaku Co., Ltd.
  • Pfizer, Inc.

  • CHAPTER 1: INTRODUCTION

    • 1.1. Report Description

    • 1.2. Key Market Segments

    • 1.3. Key Benefits

    • 1.4. Research Methodology

      • 1.4.1. Primary Research

      • 1.4.2. Secondary Research

      • 1.4.3. Analyst Tools and Models

  • CHAPTER 2: EXECUTIVE SUMMARY

    • 2.1. CXO Perspective

  • CHAPTER 3: MARKET LANDSCAPE

    • 3.1. Market Definition and Scope

    • 3.2. Key Findings

      • 3.2.1. Top Investment Pockets

      • 3.2.2. Top Winning Strategies

    • 3.3. Porter's Five Forces Analysis

      • 3.3.1. Bargaining Power of Suppliers

      • 3.3.2. Threat of New Entrants

      • 3.3.3. Threat of Substitutes

      • 3.3.4. Competitive Rivalry

      • 3.3.5. Bargaining Power among Buyers

    • 3.5. Market Dynamics

      • 3.5.1. Drivers

      • 3.5.2. Restraints

      • 3.5.3. Opportunities

  • CHAPTER 4: NON-OPIOID PAIN PATCH MARKET, BY PATCH TYPE

    • 4.1. Market Overview

      • 4.1.1 Market Size and Forecast, By Patch Type

    • 4.2. Capsaicin Patches

      • 4.2.1. Key Market Trends, Growth Factors and Opportunities

      • 4.2.2. Market Size and Forecast, By Region

      • 4.2.3. Market Share Analysis, By Country

    • 4.3. Lidocaine Patches

      • 4.3.1. Key Market Trends, Growth Factors and Opportunities

      • 4.3.2. Market Size and Forecast, By Region

      • 4.3.3. Market Share Analysis, By Country

    • 4.4. Diclofenac Patches

      • 4.4.1. Key Market Trends, Growth Factors and Opportunities

      • 4.4.2. Market Size and Forecast, By Region

      • 4.4.3. Market Share Analysis, By Country

    • 4.5. Ketoprofen Patches

      • 4.5.1. Key Market Trends, Growth Factors and Opportunities

      • 4.5.2. Market Size and Forecast, By Region

      • 4.5.3. Market Share Analysis, By Country

    • 4.6. Methyl Salicylate Patches

      • 4.6.1. Key Market Trends, Growth Factors and Opportunities

      • 4.6.2. Market Size and Forecast, By Region

      • 4.6.3. Market Share Analysis, By Country

    • 4.7. Others

      • 4.7.1. Key Market Trends, Growth Factors and Opportunities

      • 4.7.2. Market Size and Forecast, By Region

      • 4.7.3. Market Share Analysis, By Country

  • CHAPTER 5: NON-OPIOID PAIN PATCH MARKET, BY DISTRIBUTION CHANNEL

    • 5.1. Market Overview

      • 5.1.1 Market Size and Forecast, By Distribution Channel

    • 5.2. Hospital Pharmacies

      • 5.2.1. Key Market Trends, Growth Factors and Opportunities

      • 5.2.2. Market Size and Forecast, By Region

      • 5.2.3. Market Share Analysis, By Country

    • 5.3. Online Pharmacies

      • 5.3.1. Key Market Trends, Growth Factors and Opportunities

      • 5.3.2. Market Size and Forecast, By Region

      • 5.3.3. Market Share Analysis, By Country

    • 5.4. Independent Pharmacies And Drug Stores

      • 5.4.1. Key Market Trends, Growth Factors and Opportunities

      • 5.4.2. Market Size and Forecast, By Region

      • 5.4.3. Market Share Analysis, By Country

  • CHAPTER 6: NON-OPIOID PAIN PATCH MARKET, BY REGION

    • 6.1. Market Overview

      • 6.1.1 Market Size and Forecast, By Region

    • 6.2. North America

      • 6.2.1. Key Market Trends and Opportunities

      • 6.2.2. Market Size and Forecast, By Patch Type

      • 6.2.3. Market Size and Forecast, By Distribution Channel

      • 6.2.4. Market Size and Forecast, By Country

      • 6.2.5. U.S. Non-opioid Pain Patch Market

        • 6.2.5.1. Market Size and Forecast, By Patch Type
        • 6.2.5.2. Market Size and Forecast, By Distribution Channel

      • 6.2.6. Canada Non-opioid Pain Patch Market

        • 6.2.6.1. Market Size and Forecast, By Patch Type
        • 6.2.6.2. Market Size and Forecast, By Distribution Channel

      • 6.2.7. Mexico Non-opioid Pain Patch Market

        • 6.2.7.1. Market Size and Forecast, By Patch Type
        • 6.2.7.2. Market Size and Forecast, By Distribution Channel

    • 6.3. Europe

      • 6.3.1. Key Market Trends and Opportunities

      • 6.3.2. Market Size and Forecast, By Patch Type

      • 6.3.3. Market Size and Forecast, By Distribution Channel

      • 6.3.4. Market Size and Forecast, By Country

      • 6.3.5. France Non-opioid Pain Patch Market

        • 6.3.5.1. Market Size and Forecast, By Patch Type
        • 6.3.5.2. Market Size and Forecast, By Distribution Channel

      • 6.3.6. Germany Non-opioid Pain Patch Market

        • 6.3.6.1. Market Size and Forecast, By Patch Type
        • 6.3.6.2. Market Size and Forecast, By Distribution Channel

      • 6.3.7. Italy Non-opioid Pain Patch Market

        • 6.3.7.1. Market Size and Forecast, By Patch Type
        • 6.3.7.2. Market Size and Forecast, By Distribution Channel

      • 6.3.8. Spain Non-opioid Pain Patch Market

        • 6.3.8.1. Market Size and Forecast, By Patch Type
        • 6.3.8.2. Market Size and Forecast, By Distribution Channel

      • 6.3.9. UK Non-opioid Pain Patch Market

        • 6.3.9.1. Market Size and Forecast, By Patch Type
        • 6.3.9.2. Market Size and Forecast, By Distribution Channel

      • 6.3.10. Russia Non-opioid Pain Patch Market

        • 6.3.10.1. Market Size and Forecast, By Patch Type
        • 6.3.10.2. Market Size and Forecast, By Distribution Channel

      • 6.3.11. Rest Of Europe Non-opioid Pain Patch Market

        • 6.3.11.1. Market Size and Forecast, By Patch Type
        • 6.3.11.2. Market Size and Forecast, By Distribution Channel

    • 6.4. Asia-Pacific

      • 6.4.1. Key Market Trends and Opportunities

      • 6.4.2. Market Size and Forecast, By Patch Type

      • 6.4.3. Market Size and Forecast, By Distribution Channel

      • 6.4.4. Market Size and Forecast, By Country

      • 6.4.5. China Non-opioid Pain Patch Market

        • 6.4.5.1. Market Size and Forecast, By Patch Type
        • 6.4.5.2. Market Size and Forecast, By Distribution Channel

      • 6.4.6. Japan Non-opioid Pain Patch Market

        • 6.4.6.1. Market Size and Forecast, By Patch Type
        • 6.4.6.2. Market Size and Forecast, By Distribution Channel

      • 6.4.7. India Non-opioid Pain Patch Market

        • 6.4.7.1. Market Size and Forecast, By Patch Type
        • 6.4.7.2. Market Size and Forecast, By Distribution Channel

      • 6.4.8. South Korea Non-opioid Pain Patch Market

        • 6.4.8.1. Market Size and Forecast, By Patch Type
        • 6.4.8.2. Market Size and Forecast, By Distribution Channel

      • 6.4.9. Australia Non-opioid Pain Patch Market

        • 6.4.9.1. Market Size and Forecast, By Patch Type
        • 6.4.9.2. Market Size and Forecast, By Distribution Channel

      • 6.4.10. Thailand Non-opioid Pain Patch Market

        • 6.4.10.1. Market Size and Forecast, By Patch Type
        • 6.4.10.2. Market Size and Forecast, By Distribution Channel

      • 6.4.11. Malaysia Non-opioid Pain Patch Market

        • 6.4.11.1. Market Size and Forecast, By Patch Type
        • 6.4.11.2. Market Size and Forecast, By Distribution Channel

      • 6.4.12. Indonesia Non-opioid Pain Patch Market

        • 6.4.12.1. Market Size and Forecast, By Patch Type
        • 6.4.12.2. Market Size and Forecast, By Distribution Channel

      • 6.4.13. Rest of Asia Pacific Non-opioid Pain Patch Market

        • 6.4.13.1. Market Size and Forecast, By Patch Type
        • 6.4.13.2. Market Size and Forecast, By Distribution Channel

    • 6.5. LAMEA

      • 6.5.1. Key Market Trends and Opportunities

      • 6.5.2. Market Size and Forecast, By Patch Type

      • 6.5.3. Market Size and Forecast, By Distribution Channel

      • 6.5.4. Market Size and Forecast, By Country

      • 6.5.5. Brazil Non-opioid Pain Patch Market

        • 6.5.5.1. Market Size and Forecast, By Patch Type
        • 6.5.5.2. Market Size and Forecast, By Distribution Channel

      • 6.5.6. South Africa Non-opioid Pain Patch Market

        • 6.5.6.1. Market Size and Forecast, By Patch Type
        • 6.5.6.2. Market Size and Forecast, By Distribution Channel

      • 6.5.7. Saudi Arabia Non-opioid Pain Patch Market

        • 6.5.7.1. Market Size and Forecast, By Patch Type
        • 6.5.7.2. Market Size and Forecast, By Distribution Channel

      • 6.5.8. UAE Non-opioid Pain Patch Market

        • 6.5.8.1. Market Size and Forecast, By Patch Type
        • 6.5.8.2. Market Size and Forecast, By Distribution Channel

      • 6.5.9. Argentina Non-opioid Pain Patch Market

        • 6.5.9.1. Market Size and Forecast, By Patch Type
        • 6.5.9.2. Market Size and Forecast, By Distribution Channel

      • 6.5.10. Rest of LAMEA Non-opioid Pain Patch Market

        • 6.5.10.1. Market Size and Forecast, By Patch Type
        • 6.5.10.2. Market Size and Forecast, By Distribution Channel

  • CHAPTER 7: COMPETITIVE LANDSCAPE

    • 7.1. Introduction

    • 7.2. Top Winning Strategies

    • 7.3. Product Mapping Of Top 10 Player

    • 7.4. Competitive Dashboard

    • 7.5. Competitive Heatmap

    • 7.6. Top Player Positioning, 2024

  • CHAPTER 8: COMPANY PROFILES

    • 8.1. Teikoku Seiyaku Co., Ltd.

      • 8.1.1. Company Overview

      • 8.1.2. Key Executives

      • 8.1.3. Company Snapshot

      • 8.1.4. Operating Business Segments

      • 8.1.5. Product Portfolio

      • 8.1.6. Business Performance

      • 8.1.7. Key Strategic Moves and Developments

    • 8.2. Mylan N.V.

      • 8.2.1. Company Overview

      • 8.2.2. Key Executives

      • 8.2.3. Company Snapshot

      • 8.2.4. Operating Business Segments

      • 8.2.5. Product Portfolio

      • 8.2.6. Business Performance

      • 8.2.7. Key Strategic Moves and Developments

    • 8.3. GlaxoSmithKline Plc

      • 8.3.1. Company Overview

      • 8.3.2. Key Executives

      • 8.3.3. Company Snapshot

      • 8.3.4. Operating Business Segments

      • 8.3.5. Product Portfolio

      • 8.3.6. Business Performance

      • 8.3.7. Key Strategic Moves and Developments

    • 8.4. Teh Seng Pharmaceutical Mfg. Co., Ltd.

      • 8.4.1. Company Overview

      • 8.4.2. Key Executives

      • 8.4.3. Company Snapshot

      • 8.4.4. Operating Business Segments

      • 8.4.5. Product Portfolio

      • 8.4.6. Business Performance

      • 8.4.7. Key Strategic Moves and Developments

    • 8.5. Allergan Plc

      • 8.5.1. Company Overview

      • 8.5.2. Key Executives

      • 8.5.3. Company Snapshot

      • 8.5.4. Operating Business Segments

      • 8.5.5. Product Portfolio

      • 8.5.6. Business Performance

      • 8.5.7. Key Strategic Moves and Developments

    • 8.6. Pfizer, Inc.

      • 8.6.1. Company Overview

      • 8.6.2. Key Executives

      • 8.6.3. Company Snapshot

      • 8.6.4. Operating Business Segments

      • 8.6.5. Product Portfolio

      • 8.6.6. Business Performance

      • 8.6.7. Key Strategic Moves and Developments

    • 8.7. Hisamitsu Pharmaceutical Co. Inc.

      • 8.7.1. Company Overview

      • 8.7.2. Key Executives

      • 8.7.3. Company Snapshot

      • 8.7.4. Operating Business Segments

      • 8.7.5. Product Portfolio

      • 8.7.6. Business Performance

      • 8.7.7. Key Strategic Moves and Developments

    • 8.8. Acorda Therapeutics

      • 8.8.1. Company Overview

      • 8.8.2. Key Executives

      • 8.8.3. Company Snapshot

      • 8.8.4. Operating Business Segments

      • 8.8.5. Product Portfolio

      • 8.8.6. Business Performance

      • 8.8.7. Key Strategic Moves and Developments

    • 8.9. IBSA Institut Biochimque SA, Inc.

      • 8.9.1. Company Overview

      • 8.9.2. Key Executives

      • 8.9.3. Company Snapshot

      • 8.9.4. Operating Business Segments

      • 8.9.5. Product Portfolio

      • 8.9.6. Business Performance

      • 8.9.7. Key Strategic Moves and Developments

    • 8.10. Endo Pharmaceuticals, Inc.

      • 8.10.1. Company Overview

      • 8.10.2. Key Executives

      • 8.10.3. Company Snapshot

      • 8.10.4. Operating Business Segments

      • 8.10.5. Product Portfolio

      • 8.10.6. Business Performance

      • 8.10.7. Key Strategic Moves and Developments

  • LIST OF TABLES

  • TABLE 1. GLOBAL NON-OPIOID PAIN PATCH MARKET, BY PATCH TYPE, 2025-2033 ($MILLION)
  • TABLE 2. GLOBAL NON-OPIOID PAIN PATCH MARKET FOR CAPSAICIN PATCHES, BY REGION, 2025-2033 ($MILLION)
  • TABLE 3. GLOBAL NON-OPIOID PAIN PATCH MARKET FOR LIDOCAINE PATCHES, BY REGION, 2025-2033 ($MILLION)
  • TABLE 4. GLOBAL NON-OPIOID PAIN PATCH MARKET FOR DICLOFENAC PATCHES, BY REGION, 2025-2033 ($MILLION)
  • TABLE 5. GLOBAL NON-OPIOID PAIN PATCH MARKET FOR KETOPROFEN PATCHES, BY REGION, 2025-2033 ($MILLION)
  • TABLE 6. GLOBAL NON-OPIOID PAIN PATCH MARKET FOR METHYL SALICYLATE PATCHES, BY REGION, 2025-2033 ($MILLION)
  • TABLE 7. GLOBAL NON-OPIOID PAIN PATCH MARKET FOR OTHERS, BY REGION, 2025-2033 ($MILLION)
  • TABLE 8. GLOBAL NON-OPIOID PAIN PATCH MARKET, BY DISTRIBUTION CHANNEL, 2025-2033 ($MILLION)
  • TABLE 9. GLOBAL NON-OPIOID PAIN PATCH MARKET FOR HOSPITAL PHARMACIES, BY REGION, 2025-2033 ($MILLION)
  • TABLE 10. GLOBAL NON-OPIOID PAIN PATCH MARKET FOR ONLINE PHARMACIES, BY REGION, 2025-2033 ($MILLION)
  • TABLE 11. GLOBAL NON-OPIOID PAIN PATCH MARKET FOR INDEPENDENT PHARMACIES AND DRUG STORES, BY REGION, 2025-2033 ($MILLION)
  • TABLE 12. GLOBAL NON-OPIOID PAIN PATCH MARKET, BY REGION, 2025-2033 ($MILLION)
  • TABLE 13. NORTH AMERICA NON-OPIOID PAIN PATCH, BY REGION, 2025-2033 ($MILLION)
  • TABLE 14. NORTH AMERICA NON-OPIOID PAIN PATCH, BY PATCH TYPE, 2025-2033 ($MILLION)
  • TABLE 15. NORTH AMERICA NON-OPIOID PAIN PATCH, BY DISTRIBUTION CHANNEL, 2025-2033 ($MILLION)
  • TABLE 16. U.S. NON-OPIOID PAIN PATCH, BY PATCH TYPE, 2025-2033 ($MILLION)
  • TABLE 17. U.S. NON-OPIOID PAIN PATCH, BY DISTRIBUTION CHANNEL, 2025-2033 ($MILLION)
  • TABLE 18. CANADA NON-OPIOID PAIN PATCH, BY PATCH TYPE, 2025-2033 ($MILLION)
  • TABLE 19. CANADA NON-OPIOID PAIN PATCH, BY DISTRIBUTION CHANNEL, 2025-2033 ($MILLION)
  • TABLE 20. MEXICO NON-OPIOID PAIN PATCH, BY PATCH TYPE, 2025-2033 ($MILLION)
  • TABLE 21. MEXICO NON-OPIOID PAIN PATCH, BY DISTRIBUTION CHANNEL, 2025-2033 ($MILLION)
  • TABLE 22. EUROPE NON-OPIOID PAIN PATCH, BY REGION, 2025-2033 ($MILLION)
  • TABLE 23. EUROPE NON-OPIOID PAIN PATCH, BY PATCH TYPE, 2025-2033 ($MILLION)
  • TABLE 24. EUROPE NON-OPIOID PAIN PATCH, BY DISTRIBUTION CHANNEL, 2025-2033 ($MILLION)
  • TABLE 25. FRANCE NON-OPIOID PAIN PATCH, BY PATCH TYPE, 2025-2033 ($MILLION)
  • TABLE 26. FRANCE NON-OPIOID PAIN PATCH, BY DISTRIBUTION CHANNEL, 2025-2033 ($MILLION)
  • TABLE 27. GERMANY NON-OPIOID PAIN PATCH, BY PATCH TYPE, 2025-2033 ($MILLION)
  • TABLE 28. GERMANY NON-OPIOID PAIN PATCH, BY DISTRIBUTION CHANNEL, 2025-2033 ($MILLION)
  • TABLE 29. ITALY NON-OPIOID PAIN PATCH, BY PATCH TYPE, 2025-2033 ($MILLION)
  • TABLE 30. ITALY NON-OPIOID PAIN PATCH, BY DISTRIBUTION CHANNEL, 2025-2033 ($MILLION)
  • TABLE 31. SPAIN NON-OPIOID PAIN PATCH, BY PATCH TYPE, 2025-2033 ($MILLION)
  • TABLE 32. SPAIN NON-OPIOID PAIN PATCH, BY DISTRIBUTION CHANNEL, 2025-2033 ($MILLION)
  • TABLE 33. UK NON-OPIOID PAIN PATCH, BY PATCH TYPE, 2025-2033 ($MILLION)
  • TABLE 34. UK NON-OPIOID PAIN PATCH, BY DISTRIBUTION CHANNEL, 2025-2033 ($MILLION)
  • TABLE 35. RUSSIA NON-OPIOID PAIN PATCH, BY PATCH TYPE, 2025-2033 ($MILLION)
  • TABLE 36. RUSSIA NON-OPIOID PAIN PATCH, BY DISTRIBUTION CHANNEL, 2025-2033 ($MILLION)
  • TABLE 37. REST OF EUROPE NON-OPIOID PAIN PATCH, BY PATCH TYPE, 2025-2033 ($MILLION)
  • TABLE 38. REST OF EUROPE NON-OPIOID PAIN PATCH, BY DISTRIBUTION CHANNEL, 2025-2033 ($MILLION)
  • TABLE 39. ASIA-PACIFIC NON-OPIOID PAIN PATCH, BY REGION, 2025-2033 ($MILLION)
  • TABLE 40. ASIA-PACIFIC NON-OPIOID PAIN PATCH, BY PATCH TYPE, 2025-2033 ($MILLION)
  • TABLE 41. ASIA-PACIFIC NON-OPIOID PAIN PATCH, BY DISTRIBUTION CHANNEL, 2025-2033 ($MILLION)
  • TABLE 42. CHINA NON-OPIOID PAIN PATCH, BY PATCH TYPE, 2025-2033 ($MILLION)
  • TABLE 43. CHINA NON-OPIOID PAIN PATCH, BY DISTRIBUTION CHANNEL, 2025-2033 ($MILLION)
  • TABLE 44. JAPAN NON-OPIOID PAIN PATCH, BY PATCH TYPE, 2025-2033 ($MILLION)
  • TABLE 45. JAPAN NON-OPIOID PAIN PATCH, BY DISTRIBUTION CHANNEL, 2025-2033 ($MILLION)
  • TABLE 46. INDIA NON-OPIOID PAIN PATCH, BY PATCH TYPE, 2025-2033 ($MILLION)
  • TABLE 47. INDIA NON-OPIOID PAIN PATCH, BY DISTRIBUTION CHANNEL, 2025-2033 ($MILLION)
  • TABLE 48. SOUTH KOREA NON-OPIOID PAIN PATCH, BY PATCH TYPE, 2025-2033 ($MILLION)
  • TABLE 49. SOUTH KOREA NON-OPIOID PAIN PATCH, BY DISTRIBUTION CHANNEL, 2025-2033 ($MILLION)
  • TABLE 50. AUSTRALIA NON-OPIOID PAIN PATCH, BY PATCH TYPE, 2025-2033 ($MILLION)
  • TABLE 51. AUSTRALIA NON-OPIOID PAIN PATCH, BY DISTRIBUTION CHANNEL, 2025-2033 ($MILLION)
  • TABLE 52. THAILAND NON-OPIOID PAIN PATCH, BY PATCH TYPE, 2025-2033 ($MILLION)
  • TABLE 53. THAILAND NON-OPIOID PAIN PATCH, BY DISTRIBUTION CHANNEL, 2025-2033 ($MILLION)
  • TABLE 54. MALAYSIA NON-OPIOID PAIN PATCH, BY PATCH TYPE, 2025-2033 ($MILLION)
  • TABLE 55. MALAYSIA NON-OPIOID PAIN PATCH, BY DISTRIBUTION CHANNEL, 2025-2033 ($MILLION)
  • TABLE 56. INDONESIA NON-OPIOID PAIN PATCH, BY PATCH TYPE, 2025-2033 ($MILLION)
  • TABLE 57. INDONESIA NON-OPIOID PAIN PATCH, BY DISTRIBUTION CHANNEL, 2025-2033 ($MILLION)
  • TABLE 58. REST OF ASIA PACIFIC NON-OPIOID PAIN PATCH, BY PATCH TYPE, 2025-2033 ($MILLION)
  • TABLE 59. REST OF ASIA PACIFIC NON-OPIOID PAIN PATCH, BY DISTRIBUTION CHANNEL, 2025-2033 ($MILLION)
  • TABLE 60. LAMEA NON-OPIOID PAIN PATCH, BY REGION, 2025-2033 ($MILLION)
  • TABLE 61. LAMEA NON-OPIOID PAIN PATCH, BY PATCH TYPE, 2025-2033 ($MILLION)
  • TABLE 62. LAMEA NON-OPIOID PAIN PATCH, BY DISTRIBUTION CHANNEL, 2025-2033 ($MILLION)
  • TABLE 63. BRAZIL NON-OPIOID PAIN PATCH, BY PATCH TYPE, 2025-2033 ($MILLION)
  • TABLE 64. BRAZIL NON-OPIOID PAIN PATCH, BY DISTRIBUTION CHANNEL, 2025-2033 ($MILLION)
  • TABLE 65. SOUTH AFRICA NON-OPIOID PAIN PATCH, BY PATCH TYPE, 2025-2033 ($MILLION)
  • TABLE 66. SOUTH AFRICA NON-OPIOID PAIN PATCH, BY DISTRIBUTION CHANNEL, 2025-2033 ($MILLION)
  • TABLE 67. SAUDI ARABIA NON-OPIOID PAIN PATCH, BY PATCH TYPE, 2025-2033 ($MILLION)
  • TABLE 68. SAUDI ARABIA NON-OPIOID PAIN PATCH, BY DISTRIBUTION CHANNEL, 2025-2033 ($MILLION)
  • TABLE 69. UAE NON-OPIOID PAIN PATCH, BY PATCH TYPE, 2025-2033 ($MILLION)
  • TABLE 70. UAE NON-OPIOID PAIN PATCH, BY DISTRIBUTION CHANNEL, 2025-2033 ($MILLION)
  • TABLE 71. ARGENTINA NON-OPIOID PAIN PATCH, BY PATCH TYPE, 2025-2033 ($MILLION)
  • TABLE 72. ARGENTINA NON-OPIOID PAIN PATCH, BY DISTRIBUTION CHANNEL, 2025-2033 ($MILLION)
  • TABLE 73. REST OF LAMEA NON-OPIOID PAIN PATCH, BY PATCH TYPE, 2025-2033 ($MILLION)
  • TABLE 74. REST OF LAMEA NON-OPIOID PAIN PATCH, BY DISTRIBUTION CHANNEL, 2025-2033 ($MILLION)
  • TABLE 75. TEIKOKU SEIYAKU CO., LTD.: KEY EXECUTIVES
  • TABLE 76. TEIKOKU SEIYAKU CO., LTD.: COMPANY SNAPSHOT
  • TABLE 77. TEIKOKU SEIYAKU CO., LTD.: OPERATING SEGMENTS
  • TABLE 78. TEIKOKU SEIYAKU CO., LTD.: PRODUCT PORTFOLIO
  • TABLE 79. TEIKOKU SEIYAKU CO., LTD.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 80. MYLAN N.V.: KEY EXECUTIVES
  • TABLE 81. MYLAN N.V.: COMPANY SNAPSHOT
  • TABLE 82. MYLAN N.V.: OPERATING SEGMENTS
  • TABLE 83. MYLAN N.V.: PRODUCT PORTFOLIO
  • TABLE 84. MYLAN N.V.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 85. GLAXOSMITHKLINE PLC: KEY EXECUTIVES
  • TABLE 86. GLAXOSMITHKLINE PLC: COMPANY SNAPSHOT
  • TABLE 87. GLAXOSMITHKLINE PLC: OPERATING SEGMENTS
  • TABLE 88. GLAXOSMITHKLINE PLC: PRODUCT PORTFOLIO
  • TABLE 89. GLAXOSMITHKLINE PLC: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 90. TEH SENG PHARMACEUTICAL MFG. CO., LTD.: KEY EXECUTIVES
  • TABLE 91. TEH SENG PHARMACEUTICAL MFG. CO., LTD.: COMPANY SNAPSHOT
  • TABLE 92. TEH SENG PHARMACEUTICAL MFG. CO., LTD.: OPERATING SEGMENTS
  • TABLE 93. TEH SENG PHARMACEUTICAL MFG. CO., LTD.: PRODUCT PORTFOLIO
  • TABLE 94. TEH SENG PHARMACEUTICAL MFG. CO., LTD.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 95. ALLERGAN PLC: KEY EXECUTIVES
  • TABLE 96. ALLERGAN PLC: COMPANY SNAPSHOT
  • TABLE 97. ALLERGAN PLC: OPERATING SEGMENTS
  • TABLE 98. ALLERGAN PLC: PRODUCT PORTFOLIO
  • TABLE 99. ALLERGAN PLC: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 100. PFIZER, INC.: KEY EXECUTIVES
  • TABLE 101. PFIZER, INC.: COMPANY SNAPSHOT
  • TABLE 102. PFIZER, INC.: OPERATING SEGMENTS
  • TABLE 103. PFIZER, INC.: PRODUCT PORTFOLIO
  • TABLE 104. PFIZER, INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 105. HISAMITSU PHARMACEUTICAL CO. INC.: KEY EXECUTIVES
  • TABLE 106. HISAMITSU PHARMACEUTICAL CO. INC.: COMPANY SNAPSHOT
  • TABLE 107. HISAMITSU PHARMACEUTICAL CO. INC.: OPERATING SEGMENTS
  • TABLE 108. HISAMITSU PHARMACEUTICAL CO. INC.: PRODUCT PORTFOLIO
  • TABLE 109. HISAMITSU PHARMACEUTICAL CO. INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 110. ACORDA THERAPEUTICS: KEY EXECUTIVES
  • TABLE 111. ACORDA THERAPEUTICS: COMPANY SNAPSHOT
  • TABLE 112. ACORDA THERAPEUTICS: OPERATING SEGMENTS
  • TABLE 113. ACORDA THERAPEUTICS: PRODUCT PORTFOLIO
  • TABLE 114. ACORDA THERAPEUTICS: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 115. IBSA INSTITUT BIOCHIMQUE SA, INC.: KEY EXECUTIVES
  • TABLE 116. IBSA INSTITUT BIOCHIMQUE SA, INC.: COMPANY SNAPSHOT
  • TABLE 117. IBSA INSTITUT BIOCHIMQUE SA, INC.: OPERATING SEGMENTS
  • TABLE 118. IBSA INSTITUT BIOCHIMQUE SA, INC.: PRODUCT PORTFOLIO
  • TABLE 119. IBSA INSTITUT BIOCHIMQUE SA, INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 120. ENDO PHARMACEUTICALS, INC.: KEY EXECUTIVES
  • TABLE 121. ENDO PHARMACEUTICALS, INC.: COMPANY SNAPSHOT
  • TABLE 122. ENDO PHARMACEUTICALS, INC.: OPERATING SEGMENTS
  • TABLE 123. ENDO PHARMACEUTICALS, INC.: PRODUCT PORTFOLIO
  • TABLE 124. ENDO PHARMACEUTICALS, INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS

  • LIST OF FIGURES

  • FIGURE 1. GLOBAL NON-OPIOID PAIN PATCH MARKET SEGMENTATION
  • FIGURE 2. GLOBAL NON-OPIOID PAIN PATCH MARKET
  • FIGURE 3. SEGMENTATION NON-OPIOID PAIN PATCH MARKET
  • FIGURE 4. TOP INVESTMENT POCKET IN NON-OPIOID PAIN PATCH MARKET
  • FIGURE 5. MODERATE BARGAINING POWER OF BUYERS
  • FIGURE 6. MODERATE BARGAINING POWER OF SUPPLIERS
  • FIGURE 7. MODERATE THREAT OF NEW ENTRANTS
  • FIGURE 8. LOW THREAT OF SUBSTITUTION
  • FIGURE 9. HIGH COMPETITIVE RIVALRY
  • FIGURE 10. OPPORTUNITIES, RESTRAINTS AND DRIVERS: GLOBALNON-OPIOID PAIN PATCH MARKET
  • FIGURE 11. NON-OPIOID PAIN PATCH MARKET SEGMENTATION, BY BY PATCH TYPE
  • FIGURE 12. NON-OPIOID PAIN PATCH MARKET FOR CAPSAICIN PATCHES, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 13. NON-OPIOID PAIN PATCH MARKET FOR LIDOCAINE PATCHES, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 14. NON-OPIOID PAIN PATCH MARKET FOR DICLOFENAC PATCHES, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 15. NON-OPIOID PAIN PATCH MARKET FOR KETOPROFEN PATCHES, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 16. NON-OPIOID PAIN PATCH MARKET FOR METHYL SALICYLATE PATCHES, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 17. NON-OPIOID PAIN PATCH MARKET FOR OTHERS, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 18. NON-OPIOID PAIN PATCH MARKET SEGMENTATION, BY BY DISTRIBUTION CHANNEL
  • FIGURE 19. NON-OPIOID PAIN PATCH MARKET FOR HOSPITAL PHARMACIES, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 20. NON-OPIOID PAIN PATCH MARKET FOR ONLINE PHARMACIES, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 21. NON-OPIOID PAIN PATCH MARKET FOR INDEPENDENT PHARMACIES AND DRUG STORES, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 22. TOP WINNING STRATEGIES, BY YEAR, 2022-2024*
  • FIGURE 23. TOP WINNING STRATEGIES, BY DEVELOPMENT, 2022-2024*
  • FIGURE 24. TOP WINNING STRATEGIES, BY COMPANY, 2022-2024*
  • FIGURE 25. PRODUCT MAPPING OF TOP 10 PLAYERS
  • FIGURE 26. COMPETITIVE DASHBOARD
  • FIGURE 27. COMPETITIVE HEATMAP: NON-OPIOID PAIN PATCH MARKET
  • FIGURE 28. TOP PLAYER POSITIONING, 2024
  • FIGURE 29. TEIKOKU SEIYAKU CO., LTD.: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 30. TEIKOKU SEIYAKU CO., LTD.: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 31. TEIKOKU SEIYAKU CO., LTD.: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 32. MYLAN N.V.: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 33. MYLAN N.V.: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 34. MYLAN N.V.: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 35. GLAXOSMITHKLINE PLC: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 36. GLAXOSMITHKLINE PLC: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 37. GLAXOSMITHKLINE PLC: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 38. TEH SENG PHARMACEUTICAL MFG. CO., LTD.: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 39. TEH SENG PHARMACEUTICAL MFG. CO., LTD.: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 40. TEH SENG PHARMACEUTICAL MFG. CO., LTD.: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 41. ALLERGAN PLC: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 42. ALLERGAN PLC: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 43. ALLERGAN PLC: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 44. PFIZER, INC.: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 45. PFIZER, INC.: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 46. PFIZER, INC.: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 47. HISAMITSU PHARMACEUTICAL CO. INC.: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 48. HISAMITSU PHARMACEUTICAL CO. INC.: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 49. HISAMITSU PHARMACEUTICAL CO. INC.: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 50. ACORDA THERAPEUTICS: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 51. ACORDA THERAPEUTICS: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 52. ACORDA THERAPEUTICS: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 53. IBSA INSTITUT BIOCHIMQUE SA, INC.: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 54. IBSA INSTITUT BIOCHIMQUE SA, INC.: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 55. IBSA INSTITUT BIOCHIMQUE SA, INC.: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 56. ENDO PHARMACEUTICALS, INC.: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 57. ENDO PHARMACEUTICALS, INC.: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 58. ENDO PHARMACEUTICALS, INC.: REVENUE SHARE, BY REGION, 2024 (%)

Purchase Full Report of
Non-opioid Pain Patch Market

PURCHASE OPTIONS



* Taxes/Fees, If applicable will be added during checkout. All prices in USD.

Have a question ?

Need to add more ?

Avail up to 30% discount on subscription plans on


Avenue

© 2025 Allied Market Research. All Rights Reserved